In a surprising move, AstraZeneca has announced the worldwide withdrawal of its COVID-19 vaccine, Vaxzevria. The pharmaceutical giant cited a "surplus of available updated vaccines" as the primary reason for this decision. With the development of multiple variant COVID-19 vaccines, the demand for Vaxzevria has significantly declined, leading AstraZeneca to cease manufacturing and supply of the vaccine. The company has begun the process of withdrawing Vaxzevria's marketing authorizations across Europe, marking a significant shift in its vaccination efforts.
Recent revelations have shed light on potential side effects of the AstraZeneca vaccine, including blood clots and low blood platelet counts. Court documents filed by the Anglo-Swedish drugmaker have acknowledged these risks, prompting concerns among health authorities and the public. The decision to withdraw the vaccine may have been influenced by these safety concerns, as well as the availability of newer and potentially safer COVID-19 vaccines on the market.
AstraZeneca submitted its application to withdraw the vaccine on March 5, with the decision coming into effect on May 7. This development marks a significant turning point in the global vaccination campaign against COVID-19, with AstraZeneca shifting its focus to other areas of pharmaceutical research, such as respiratory syncytial virus vaccines and obesity drugs. The company's decision to diversify its portfolio comes amid a slowdown in growth following the decline in COVID-19 medicine sales.
The Serum Institute of India (SII), which produced AstraZeneca's COVID-19 vaccine under the name Covishield, has also halted manufacturing and supply of the doses since December 2021. This further underscores the shifting landscape in the global fight against the pandemic, with a greater emphasis on newer and potentially more effective vaccines. As AstraZeneca navigates this transition, the impact of its decision to withdraw the COVID-19 vaccine will be closely monitored by health authorities and the public alike.